Depomed Sues Cadila, Zydus Over Generic Gralise

Law360, New York (May 11, 2012, 12:11 PM EDT) -- Drug company Depomed Inc. lodged a patent infringement suit Wednesday in New Jersey in an effort to block plans by Indian drugmaker Cadila Healthcare Ltd. and its U.S. subsidiary to market a generic version of epilepsy medication Gralise.

California-based Depomed brought suit after Cadila and Zydus Pharmaceuticals (USA) Inc. sought federal approval of an abbreviated new drug application to make and sell a generic version of Gralise before Depomed’s six patents had expired.

“Zydus has declared its intent to manufacture, use, offer to sell or sell...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.